Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 With Immunotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma of B-Cell Origin

Next Previous
Search
Trial Profile

A Multi-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 With Immunotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma of B-Cell Origin

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AB 101 Artiva Biotherapeutics (Primary) ; Bendamustine (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Interleukin-2 (Primary) ; Rituximab (Primary)
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Artiva Biotherapeutics

Most Recent Events

  • 28 Apr 2025 According to an Artiva Biotherapeutics Media Release, the company will have a poster presentation on new longer-term Phase 1/2 data for AlloNK (also known as AB-101) in patients with relapsed/refractory B-cell non-Hodgkin lymphoma at the upcoming American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting taking place May 13-17, 2025, in New Orleans, Louisiana.
  • 24 Mar 2025 According to an Artiva Biotherapeutics Media Release, company is looking forward to share initial data from the study at a medical conference in 2025.
  • 07 Aug 2023 Planned number of patients changed from 93 to 108.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top